[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @COR2EDMedEd COR2ED COR2ED posts on X about matterhorn, topics, future of the most. They currently have XXXXX followers and X posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::719588640171696129/interactions)  - X Week XXXXXX +86,116% - X Months XXXXXXX +22% - X Year XXXXXXX -XX% ### Mentions: X [#](/creator/twitter::719588640171696129/posts_active)  - X Week X +400% - X Months XX +233% - X Year XX +7.70% ### Followers: XXXXX [#](/creator/twitter::719588640171696129/followers)  - X Week XXXXX +1.90% - X Months XXXXX +34% - X Year XXXXX +42% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::719588640171696129/influencer_rank)  ### Social Influence [#](/creator/twitter::719588640171696129/influence) --- **Social category influence** [finance](/list/finance) XX% [travel destinations](/list/travel-destinations) XX% **Social topic influence** [matterhorn](/topic/matterhorn) 40%, [topics](/topic/topics) 20%, [future of](/topic/future-of) XX% **Top accounts mentioned or mentioned by** [@lizzysmyth1](/creator/undefined) [@netconnectinfo](/creator/undefined) [@helops79](/creator/undefined) [@profkherrmann](/creator/undefined) [@oncbrothers](/creator/undefined) [@nanets1](/creator/undefined) [@diceeurope](/creator/undefined) [@oncoalert](/creator/undefined) ### Top Social Posts [#](/creator/twitter::719588640171696129/posts) --- Top posts by engagements in the last XX hours "HR+/HER2 metastatic breast cancer can be complex to treat particularly once endocrine resistance develops. In this case-based video Dr Barbara Pistilli discusses the journey of a pretreated patient with HR+/HER2 (IHC 0) mBC who developed endocrine resistance. She explores: ADCs as effective manageable alternatives to ChT Mechanism of action & available options Strategies for managing AEs Watch the case study on YouTube here: #BreastCancer #MedEd #Oncology This educational programme is supported by an Independent Educational Grant from AstraZeneca" [X Link](https://x.com/COR2EDMedEd/status/1980626651860898173) [@COR2EDMedEd](/creator/x/COR2EDMedEd) 2025-10-21T13:26Z 1004 followers, XX engagements "Just released Gastric & gastroesophageal cancer update from ESMO25 📺 Dr @LizzySmyth1 shares her gastric & GE cancer highlights & reviews the latest data from MATTERHORN trial This independent programme is supported by COR2ED" [X Link](https://x.com/COR2EDMedEd/status/1980936719882166537) [@COR2EDMedEd](/creator/x/COR2EDMedEd) 2025-10-22T09:58Z 1004 followers, 45K engagements "📢Just released Gastric & #gastroesophageal cancer update from #ESMO25 📺 Dr @LizzySmyth1 shares her #gastric & GE cancer highlights & reviews the latest data from #MATTERHORN trial See more updates from #ESMO This independent programme is supported by COR2ED #MedEd #GastricCancer #GIcancer" [X Link](https://x.com/COR2EDMedEd/status/1979915435643396568) [@COR2EDMedEd](/creator/x/COR2EDMedEd) 2025-10-19T14:19Z XXX followers, XXX engagements "Join the discussion Experts will review the latest data on gastric & gastroesophageal cancer from ESMO25 in a virtual Experts Knowledge Share What will new data mean for clinical practice 19th November 17:00 -18:15 CET / 11:00 -12:15 EST Topics: -Future of targeted therapy & IO -Peri-operative approaches -Developments in ESCC -Panel discussion/Q&A Meeting Chair: Dr @LizzySmyth1 (UK) Co-Chairs: Prof. Aziz Zaanan (France) & Prof. Markus Moehler (Germany) Endorsed by: @dice_europe This independent programme is supported by an educational grant from Amgen" [X Link](https://x.com/COR2EDMedEd/status/1981387163431252254) [@COR2EDMedEd](/creator/x/COR2EDMedEd) 2025-10-23T15:48Z XXX followers, XX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@COR2EDMedEd COR2EDCOR2ED posts on X about matterhorn, topics, future of the most. They currently have XXXXX followers and X posts still getting attention that total XXXXX engagements in the last XX hours.
Social category influence finance XX% travel destinations XX%
Social topic influence matterhorn 40%, topics 20%, future of XX%
Top accounts mentioned or mentioned by @lizzysmyth1 @netconnectinfo @helops79 @profkherrmann @oncbrothers @nanets1 @diceeurope @oncoalert
Top posts by engagements in the last XX hours
"HR+/HER2 metastatic breast cancer can be complex to treat particularly once endocrine resistance develops. In this case-based video Dr Barbara Pistilli discusses the journey of a pretreated patient with HR+/HER2 (IHC 0) mBC who developed endocrine resistance. She explores: ADCs as effective manageable alternatives to ChT Mechanism of action & available options Strategies for managing AEs Watch the case study on YouTube here: #BreastCancer #MedEd #Oncology This educational programme is supported by an Independent Educational Grant from AstraZeneca"
X Link @COR2EDMedEd 2025-10-21T13:26Z 1004 followers, XX engagements
"Just released Gastric & gastroesophageal cancer update from ESMO25 📺 Dr @LizzySmyth1 shares her gastric & GE cancer highlights & reviews the latest data from MATTERHORN trial This independent programme is supported by COR2ED"
X Link @COR2EDMedEd 2025-10-22T09:58Z 1004 followers, 45K engagements
"📢Just released Gastric & #gastroesophageal cancer update from #ESMO25 📺 Dr @LizzySmyth1 shares her #gastric & GE cancer highlights & reviews the latest data from #MATTERHORN trial See more updates from #ESMO This independent programme is supported by COR2ED #MedEd #GastricCancer #GIcancer"
X Link @COR2EDMedEd 2025-10-19T14:19Z XXX followers, XXX engagements
"Join the discussion Experts will review the latest data on gastric & gastroesophageal cancer from ESMO25 in a virtual Experts Knowledge Share What will new data mean for clinical practice 19th November 17:00 -18:15 CET / 11:00 -12:15 EST Topics: -Future of targeted therapy & IO -Peri-operative approaches -Developments in ESCC -Panel discussion/Q&A Meeting Chair: Dr @LizzySmyth1 (UK) Co-Chairs: Prof. Aziz Zaanan (France) & Prof. Markus Moehler (Germany) Endorsed by: @dice_europe This independent programme is supported by an educational grant from Amgen"
X Link @COR2EDMedEd 2025-10-23T15:48Z XXX followers, XX engagements
/creator/x::COR2EDMedEd